Aurora Cannabis Inc (ACB)vsHaleon plc (HLN)
ACB
Aurora Cannabis Inc
$2.87
-3.70%
HEALTHCARE · Cap: $188.30M
HLN
Haleon plc
$8.95
+1.79%
HEALTHCARE · Cap: $39.55B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 2856% more annual revenue ($11.03B vs $373.12M). HLN leads profitability with a 15.1% profit margin vs -22.5%. HLN earns a higher WallStSmart Score of 63/100 (C+).
ACB
Avoid34
out of 100
Grade: F
HLN
Buy63
out of 100
Grade: C+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Earnings expanding 92.0% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Operating margin of 2.3%
Weak financial health signals
ROE of -7.9% — below average capital efficiency
Expensive relative to growth rate
0.6% revenue growth
Grey zone — moderate risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ACB
The strongest argument for ACB centers on Price/Book, Debt/Equity.
Bull Case : HLN
The strongest argument for HLN centers on EPS Growth, P/E Ratio, Price/Book. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bear Case : ACB
The primary concerns for ACB are Market Cap, Operating Margin, Piotroski F-Score.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth, Altman Z-Score.
Key Dynamics to Monitor
ACB profiles as a turnaround stock while HLN is a value play — different risk/reward profiles.
ACB carries more volatility with a beta of 1.34 — expect wider price swings.
ACB is growing revenue faster at 6.8% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
HLN scores higher overall (63/100 vs 34/100), backed by strong 15.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aurora Cannabis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Aurora Cannabis Inc. produces and distributes medical cannabis products globally. The company is headquartered in Edmonton, Canada.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a prominent global consumer health company formed from a spin-off of GlaxoSmithKline, focusing on delivering innovative health solutions across a diverse portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. By concentrating on key segments such as oral care, pain relief, and dietary supplements, Haleon effectively addresses the dynamic needs of consumers while capitalizing on strong brand equity. The company's dedication to sustainability and relentless innovation, combined with strategic investments in product development, positions it advantageously for sustained long-term growth, thereby enhancing health outcomes and maximizing shareholder value.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?